“Myelofibrosis therapy today is still limited to the four JAK inhibitors,” he noted. Additionally, Bose discussed how can patients with myelofibrosis can work with their care team to understand their treatment options in another conversation with CURE. TranscriptCan you walk us through the current treatment landscape for myelofibrosis, and how you decide which therapies are best suited for individual patients? Myelofibrosis therapy today is still limited to the four JAK inhibitors. But most patients will eventually need JAK inhibitors because they tend to have some degree of splenomegaly and symptoms.